This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Infection severity: infections causing symptoms, duration of symptoms, hospitalisation amongst symptomatic patients, fulminant illness amongst symptomatic patients, liver transplantation among patients with fulminant illness, deaths among symptomatic patients, duration of work loss for hospitalised patients, duration of illness for non-hospitalised patients.
The following outcomes of hepatitis A vaccination were assessed in the review: long term efficacy following complete vaccination schedule; protective efficacy following two vaccine doses; and, protective efficacy following a single dose vaccine.
Study designs and other criteria for inclusion in the review
Parameter estimates were obtained from published reports and national databases (Centres for Disease Control and Prevention, USA). Data were also used from a case study series and estimates of patient survival and vaccine effectiveness derived by an expert panel. The authors did not report predefined study designs or other inclusion and exclusion criteria required for studies to be included in the review.
Sources searched to identify primary studies
The sources searched to identify primary studies were not reported.
Criteria used to ensure the validity of primary studies
The study did not report the criteria used to ensure the validity of primary studies.
Methods used to judge relevance and validity, and for extracting data
The authors did not report the criteria used to judge the relevance and validity of data or to determine which data were extracted.
Number of primary studies included
Seven primary studies were included in the review.
Methods of combining primary studies
Correspondence with the authors indicates that an expert panel was used to combine data from different sources.
Investigation of differences between primary studies
The authors did not investigate the differences between primary studies.
Results of the review
The following results of outcomes of hepatitis A were reported:
Infection incidence:
annual infection risk 15.7/10,000.
Infection severity:
infections causing symptoms 73%, duration of symptoms 38 days, hospitalisation amongst symptomatic patients 10%, fulminant illness amongst symptomatic patients 9/10,000, liver transplantation among patients with fulminant illness 23%, deaths among symptomatic patients 18/10,000, duration of work loss for hospitalised patients 15.5 days, duration of illness for non-hospitalised patients 32.2 days.
The following results of outcomes of hepatitis A vaccination were reported in the review: long term efficacy following complete vaccination schedule: 93 to 95%; protective efficacy following two vaccine doses were estimated to be 95% at 5 years and 10 years, 90% at 20 years, 81% at 30 years and 74% at 50 years, and, protective efficacy following a single dose vaccine were estimated to be 73% at 5 years, 62% at 10 years, 42% at 20 years, 32% at 30 years and 21% at 50 years.
Measure of benefits used in the economic analysis
The authors used years of life saved (YOLS) as a measure of economic benefit. Hepatitis A deaths were converted into life years lost based on the age of each fatal case and life expectancies for the general US population. YOLS were converted to present values using a 3% annual discount rate.
Direct costs
Resource use and costs were not reported separately. Correspondence with the authors indicates that the resource use data were derived from one published paper. The following costs of hepatitis A infection were included in the analysis: Estimates were derived on the basis that each notification would take 80 public health personnel hours and an average of 244 immune globulin doses were assumed to be administered following each public notification.
The cost of vaccination was estimated from a programme developed by SmithKline Beecham and the National Restaurant Association. Median vaccine and administration costs were reported as $43 and $10.75 per dose respectively.
Treatment costs for outpatients and inpatients without fulminant disease were estimated from a case series study. Treatment costs for patients with fulminant disease were derived from an expert panel, a report of liver transplant costs and estimates of transplant patient survival.
Costs were adjusted to 1997 levels using the Consumer Price Index for Medical Care and the Employment Cost Index and a discount rate of 3% was reported.
Statistical analysis of costs
No statistical analysis of costs was reported.
Indirect Costs
The following indirect costs were included in the analysis:
Work loss day, FSW infection $58; and, Work loss day, food-associated infection $116.
The authors stated that the work loss duration was derived from a case series study. For food-associated cases, work loss was valued using national data describing workforce participation and earnings. The authors stated that FSW loss was assigned a lower value because wages in that sector are 49% of those in the private sector. Although costs incurred by the health system were considered, those incurred by the food services business were not.
Currency

US dollars ($). No currency conversions were reported.
Sensitivity analysis
The authors reported that several sensitivity analyses were conducted by varying parameters thought to have the greatest effects on cost effectiveness. The sensitivity analysis was conducted by changing the following parameters: discount rates; estimates of food service employment duration; probability of food borne outbreak from an infected FSW; and, probability of public notification of an infected FSW.
the structure of the model was validated. The authors conducted sensitivity analyses to assess the robustness of the results to changes in the values of parameters. Not all parameters were included in the sensitivity analysis and the authors do not report the criteria for selection of the parameters to be tested. These factors mean that it is difficult to assess the validity of the data and the model used to estimate the impact of vaccinating FSWs against hepatitis A.
Validity of estimate of measure of benefit
The authors used life years lost as the summary measure of health benefit. This excludes any impact of changes in morbidity on the overall health and social well being of the population at risk of hepatitis A or those vaccinated. The authors did not report any long term sequelae (other than death) of hepatitis A or side-effects of vaccination. In correspondence subsequent to this abstract being written, the authors report that, for survivors, there are no adverse long term sequelae associated with hepatitis A. The authors also note in this correspondence that quality of life effects of hepatitis A will be published separately.
Validity of estimate of costs
Costs and quantities were not reported separately. Costs were discounted and adjusted to the same price year. The estimates of cost were derived from published literature, databases and expert opinion. The authors did not report any assessment of the validity of the data from these sources and did not report the methods used to combine data from different sources. Costs of any long term health sequelae from hepatitis A infection or from side effects of vaccination were not included. Although the authors reported that costs were estimated from both a societal and health system perspective the full range of indirect costs were not included. The authors stated that economic losses may also accrue to business owners when FSW are infected with hepatitis A. However, these costs were not included in the analysis. The reader should decide whether the omitted costs are likely to affect the authors' conclusions.
